Juan J. Gallegos

Juan J. Gallegos

Auto-generated profile, based on publicly available information

Juan J. Gallegos

The University of Texas MD Anderson Cancer Center 2 Department of Hematopoietic Biology and Malignancy Houston, Texas

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
TJTejas Jammihal
Tejas Jammihal
RSRenee Maria Saliby
Renee Maria Saliby
CLChris Labaki
Chris Labaki
HSHanna Soulati
Hanna Soulati
JGJuan Gallegos
Juan Gallegos
SSSachet A. Shukla
Sachet A. Shukla

16 June 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
TLTzung-Huei Lai
Tzung-Huei Lai
HOHatice Gulcin Ozer
Hatice Gulcin Ozer
PGPierluigi Gasparini
Pierluigi Gasparini
Giovanni NigitaGiovanni Nigita
Giovanni Nigita
RDRosario Distefano
Rosario Distefano
DSDeepa Sampath
Deepa Sampath
Chronic lymphocytic leukemia (CLL) is a quiescent B-cell malignancy that depends on transcriptional dysregulation for survival. The histone deacetylases are transcriptional regulators whose role within the regulatory chromatin and consequence on the CLL transcriptome is poorly characterized. Here, we profiled and integrated the genome-wide occupancy of HDAC1, BRD4, H3K27Ac, and H3K9Ac signals with chromatin accessibility, Pol2 occupancy, and target expression signatures in CLL cells. We identified that when HDAC1 was recruited within super-enhancers (SEs) marked by acetylated H3K27 and BRD4, it functioned as a transcriptional activator that drove the de novo expression of select genes to facilitate survival and progression in CLL. Targeting HDACs reduced BRD4 and Pol2 engagement to downregulate the transcript and proteins levels of specific oncogenic driver genes in CLL such as BLK, a key mediator of the B-cell receptor pathway, core transcription factors such as PAX5 and IKZF3, and the antiapoptotic gene, BCL2. Concurrently, HDAC1, when recruited in the absence of SEs, repressed target gene expression. HDAC inhibition reversed silencing of a defined set of protein-coding and noncoding RNA genes. We focused on a specific set of microRNA genes and showed that their upregulation was inversely correlated with the expression of CLL-specific survival, transcription factor, and signaling genes. Our findings identify that the transcriptional activator and repressor functions of HDACs cooperate within the same tumor to establish the transcriptional dependencies essential for survival in CLL.

2 November 2026
Verified
Other
Open access
NSNakul M. Shah
Nakul M. Shah
BABeatriz Alvarado-Hernandez
Beatriz Alvarado-Hernandez
XCXinyue Chen
Xinyue Chen
QKQuentin Kimana
Quentin Kimana
FNFelicity Namayanja
Felicity Namayanja
SSSachet A. Shukla
Sachet A. Shukla
Supplementary Tables1 from Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma

18 August 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
NSNakul M. Shah
Nakul M. Shah
BABeatriz Alvarado-Hernandez
Beatriz Alvarado-Hernandez
XCXinyue Chen
Xinyue Chen
QKQuentin Kimana
Quentin Kimana
FNFelicity Namayanja
Felicity Namayanja
SSSachet A. Shukla
Sachet A. Shukla
Purpose: Intrahepatic cholangiocarcinoma (iCCA) is increasing in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody–drug conjugates have expanded therapeutic opportunities across many tumor types, including HER2/neu-altered iCCA. However, validated and prevalent cell surface targets suitable for biologic therapies remain uncommon in iCCA, representing a critical bottleneck to the development of novel targeted treatments. In particular, gene-level analyses overlook tumor-enriched protein isoforms produced through alternative splicing. Experimental Design: To address this gap, we applied a novel isoform-resolved proteogenomic approach comprising transcriptomics, in silico translation, and cell surfaceomics to identify prevalent cell surface targets in iCCA and further assessed their specificity through analysis of expression data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression datasets. Results: This approach identified a unique peptide corresponding to fibroblast growth factor receptor 2b (FGFR2b), a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c. FGFR2b was the predominant FGFR2 isoform in biliary tract cancer, including iCCA, in both our institutional cohort (88.6%) and TCGA (88.2%). FGFR2 fusions, in particular, were associated with high FGFR2b expression. High FGFR2b expression was associated with improved surgical outcomes, epithelial differentiation, and reduced CD8+ T-cell infiltration. Orthogonal validation using IHC in a subset of 20 patients with available tissue samples confirmed membrane-bound FGFR2b expression in 31.6% of iCCA cases, including all patients with FGFR2 fusions. Conclusions: Our findings identify FGFR2b as a prevalent and compelling therapeutic target in iCCA and provide a strong rationale for ongoing and future FGFR2b-targeted clinical trials.